The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for five new drugs, including Madrigal’s Rezdiffra (resmetirom) for metabolic dysfunction-associated steatohepatitis and Springworks’ Ogsiveo (nirogacestat) for desmoid tumors. Concurrently, CHMP has initiated a re-examination of Eli Lilly’s Alzheimer’s drug Kisunla following recent health technology appraisals questioning its cost-effectiveness. These recommendations mark significant regulatory milestones impacting therapeutic options across diverse disease areas in Europe.